Aussie court tosses Lipitor suit against Pfizer; Novartis nabs FDA approval for multiple myeloma med;

> Pfizer's ($PFE) strategy of offering steep Lipitor rebates as the drug's patent neared expiration didn't constitute anticompetitive conduct, an Australian judge said, tossing a lawsuit filed by the Australian Competition and Consumer Commission. Report (sub. req.)

> Novartis ($NVS) won FDA approval for its multiple myeloma drug Farydak, as a third line treatment. Report

> The global cancer drug market is expected to hit $111 billion by 2020, new market research shows. Report

> Hospira ($HSP) and Celltrion launched their biosimilar versions of Remicade in Europe, where the brand earned €2 billion last year. Report (reg. req.)

And Finally... Preventive treatment with an HIV drug reduced infection by 86% in gay men at high risk of contracting the disease. Report